Blood Group and COVID-19 Transmission and Mortality in Patients With Malignant Disease

Aim: The study aimed to investigate risk factors affecting the transmission of and mortality from COVID-19 in patients diagnosed with a malignant disease. In this context, ABO blood groups, gender, age, type of malignant disease, type of anti-tumoral agents, comorbidities and stage were examined....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Senar Ebinç, Zeynep Oruç, Ziya Kalkan, Zuhat Urakçı, Muhammet Ali Kaplan, Mehmet Küçüköner, Abdurrahman Işıkdoğan
Formato:	article
Lenguaje:	EN
Publicado:	Faculty of Medicine Osijek 2021
Materias:	covid-19 abo blood group system neoplasm Medicine R
Acceso en línea:	http://dx.doi.org/10.26332/seemedj.v5i2.205 https://doaj.org/article/f0ccc57eb9714c668263ae07ac887d5b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f0ccc57eb9714c668263ae07ac887d5b
record_format	dspace
spelling	oai:doaj.org-article:f0ccc57eb9714c668263ae07ac887d5b2021-11-29T13:42:11ZBlood Group and COVID-19 Transmission and Mortality in Patients With Malignant Diseasehttp://dx.doi.org/10.26332/seemedj.v5i2.2052459-9484https://doaj.org/article/f0ccc57eb9714c668263ae07ac887d5b2021-11-01T00:00:00Zhttp://seemedj.mefos.unios.hr/index.php/seemedj/article/view/205/112https://doaj.org/toc/2459-9484Aim: The study aimed to investigate risk factors affecting the transmission of and mortality from COVID-19 in patients diagnosed with a malignant disease. In this context, ABO blood groups, gender, age, type of malignant disease, type of anti-tumoral agents, comorbidities and stage were examined. Materials and Methods: Files of 1,256 patients who presented to our clinic between March and December 2020 were retrospectively reviewed. Patients diagnosed with a malignant disease who became infected with COVID-19 and those who did not were compared with regard to demographic, clinical characteristics and laboratory results (status of having been infected with COVID-19, ABO blood groups). Results: Of 1256 patients in total, 72 (5.7%) were diagnosed with COVID-19. Median age of cancer patients infected with COVID-19 was 53 years (18-80). The most common types of cancer included gastrointestinal cancer (22.2%), breast cancer (20.8%), genitourinary cancer (20.8%) and lung cancer (16.7%). Of the patients diagnosed with COVID-19, 18.1% (n=13) died. Multivariate analysis identified disease stage as an independent prognostic factor for the risk of mortality [HR: 0.07, 95% CI (0.007-0.74), (p=0.02)]. A comparison of patients who became infected with COVID-19 and those who did not with regard to ABO blood groups (p=0.39) showed no statistically significant differences between the two groups. There was also no correlation between ABO blood groups and the risk of COVID-19-related mortality (p=0.83). Conclusion: In patients suffering from malignant diseases, the ABO blood type exhibited no correlation with the risk of COVID-19 transmission and mortality. This study determined the presence of metastatic disease as a negative prognostic factor. Patients suffering from a metastatic malignant disease represent a high risk group for COVID-19 and should be treated using all necessary precautions.Senar EbinçZeynep OruçZiya KalkanZuhat UrakçıMuhammet Ali KaplanMehmet KüçükönerAbdurrahman IşıkdoğanFaculty of Medicine Osijekarticlecovid-19abo blood group systemneoplasmMedicineRENSoutheastern European Medical Journal, Vol 5, Iss 2, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	covid-19 abo blood group system neoplasm Medicine R
spellingShingle	covid-19 abo blood group system neoplasm Medicine R Senar Ebinç Zeynep Oruç Ziya Kalkan Zuhat Urakçı Muhammet Ali Kaplan Mehmet Küçüköner Abdurrahman Işıkdoğan Blood Group and COVID-19 Transmission and Mortality in Patients With Malignant Disease
description	Aim: The study aimed to investigate risk factors affecting the transmission of and mortality from COVID-19 in patients diagnosed with a malignant disease. In this context, ABO blood groups, gender, age, type of malignant disease, type of anti-tumoral agents, comorbidities and stage were examined. Materials and Methods: Files of 1,256 patients who presented to our clinic between March and December 2020 were retrospectively reviewed. Patients diagnosed with a malignant disease who became infected with COVID-19 and those who did not were compared with regard to demographic, clinical characteristics and laboratory results (status of having been infected with COVID-19, ABO blood groups). Results: Of 1256 patients in total, 72 (5.7%) were diagnosed with COVID-19. Median age of cancer patients infected with COVID-19 was 53 years (18-80). The most common types of cancer included gastrointestinal cancer (22.2%), breast cancer (20.8%), genitourinary cancer (20.8%) and lung cancer (16.7%). Of the patients diagnosed with COVID-19, 18.1% (n=13) died. Multivariate analysis identified disease stage as an independent prognostic factor for the risk of mortality [HR: 0.07, 95% CI (0.007-0.74), (p=0.02)]. A comparison of patients who became infected with COVID-19 and those who did not with regard to ABO blood groups (p=0.39) showed no statistically significant differences between the two groups. There was also no correlation between ABO blood groups and the risk of COVID-19-related mortality (p=0.83). Conclusion: In patients suffering from malignant diseases, the ABO blood type exhibited no correlation with the risk of COVID-19 transmission and mortality. This study determined the presence of metastatic disease as a negative prognostic factor. Patients suffering from a metastatic malignant disease represent a high risk group for COVID-19 and should be treated using all necessary precautions.
format	article
author	Senar Ebinç Zeynep Oruç Ziya Kalkan Zuhat Urakçı Muhammet Ali Kaplan Mehmet Küçüköner Abdurrahman Işıkdoğan
author_facet	Senar Ebinç Zeynep Oruç Ziya Kalkan Zuhat Urakçı Muhammet Ali Kaplan Mehmet Küçüköner Abdurrahman Işıkdoğan
author_sort	Senar Ebinç
title	Blood Group and COVID-19 Transmission and Mortality in Patients With Malignant Disease
title_short	Blood Group and COVID-19 Transmission and Mortality in Patients With Malignant Disease
title_full	Blood Group and COVID-19 Transmission and Mortality in Patients With Malignant Disease
title_fullStr	Blood Group and COVID-19 Transmission and Mortality in Patients With Malignant Disease
title_full_unstemmed	Blood Group and COVID-19 Transmission and Mortality in Patients With Malignant Disease
title_sort	blood group and covid-19 transmission and mortality in patients with malignant disease
publisher	Faculty of Medicine Osijek
publishDate	2021
url	http://dx.doi.org/10.26332/seemedj.v5i2.205 https://doaj.org/article/f0ccc57eb9714c668263ae07ac887d5b
work_keys_str_mv	AT senarebinc bloodgroupandcovid19transmissionandmortalityinpatientswithmalignantdisease AT zeyneporuc bloodgroupandcovid19transmissionandmortalityinpatientswithmalignantdisease AT ziyakalkan bloodgroupandcovid19transmissionandmortalityinpatientswithmalignantdisease AT zuhaturakcı bloodgroupandcovid19transmissionandmortalityinpatientswithmalignantdisease AT muhammetalikaplan bloodgroupandcovid19transmissionandmortalityinpatientswithmalignantdisease AT mehmetkucukoner bloodgroupandcovid19transmissionandmortalityinpatientswithmalignantdisease AT abdurrahmanisıkdogan bloodgroupandcovid19transmissionandmortalityinpatientswithmalignantdisease
_version_	1718407381071691776

Blood Group and COVID-19 Transmission and Mortality in Patients With Malignant Disease

Ejemplares similares